Neurologic Clinics 1993: Vol 11 Index

19 Pages·1993·3.8 MB·English

CUMULATIVE INDEX 1993
Volume 11
February BEHAVIORAL NEUROLOGY, pages 1-237
NEUROCARDIOLOGY, pages 239-501
NEUROLOGIC COMPLICATIONS OF DRUG AND ALCOHOL
ABUSE, pages 503-735
November EPILEPSY I: DIAGNOSIS AND TREATMENT, pages 737-990
Note: Page numbers of issue and article titles are in boldface type.
Abdominal pain, recurrent, seizures and, abuse of, cerebellar degeneration due to,
743 628
Abscess, brain, drug-related, 596 dementia due to, 646-655. See also De-
infective endocarditis and, 425-426 me;:tia, alcoholic, primary.
neurologic complications, 447-448 dyskinesias due to, 627-628
Absence seizure(s), 761-763 essential myoclonus due to, 626
Abstinence, precipitated, described, 508 essential tremor due to, 625-626
protracted, described, 508 fetal effects, 711-715. See also Fetal al-
Abulia, cognitive rehabilitation in, 47 cohol syndrome.
Acquired epileptic aphasia, 764 CNS involvement, 713-714
Acquired hepatocerebral degeneration, growth-related, 713
645-646 malformations, 712-713
Acquired immunodeficiency syndrome neurobehavioral, 714-715
(AIDS), clinical syndromes of, 609 movement disorders due to, 625-629
defined, 605 muscular effects, 700-701
epidemiology, 606 nerve root effects, 697-698
stroke in, 578-579 neurologic complications, issue on,
Acute brain syndrome, infective 503-728
endocarditis and, 426 Parkinson’s disease due to, 626
Acute tolerance, described, 507 peripheral nerve effects, 697-698
Addiction, described, 509 plexus effects, 697-698
Adolescents, hashish use by, 665 postnatal, 714
marijuana effects on, 667-668 pregnancy effects, 713
marijuana use by, 665 seizures related to, 565-569. See also
Affective disorders. See also Depression. Seizure(s), alcohol-related.
bipolar, in multiple sclerosis, 199 stroke related to, 585-586
Afferent nerve fibers, cardiac, 240-241 withdrawal parkinsonism due to, 627-
Afferent receptors, in neural cardiovascular 628
control, 258-259 Alcohol intoxication, seizures and, 746
Age, as factor with opioid use, 515-516 Alcohol liver disease, movement disorders
Aggression, epilepsy and, 139-140 associated with, 628-629
Aging, premature, alcoholism and, 211 Alcohol tremor, 626-627
AIDS. See Acquired immunodeficiency Alcohol withdrawal, role of, 566-567
syndrome. Alcohol withdrawal seizure(s), clinical
Alcohol. See also Ethanol. features, 567-568
974 CUMULATIVE INDEX 1993
Alcohol withdrawal seizure(s) (Continued) intracranial mycotic, infective endocardi-
management, 569 tis and, 425
pathophysiology, 566 left ventricular, postinfarction, 405-406
Alcohol withdrawal syndrome, fetal effects, Anosognosia, cognitive rehabilitation in,
715 44-46
Alcoholic cerebellar degeneration, ethanol Antibiotics, in infective endocarditis, 431-
and, 527 432
Alcoholism, cognitive impairment due to, Anticholinergic(s), abuse of, side effects,
recoverability of, 212-213 559
epiiepsy due to, 568 described, 559
muscular effects, 700-701 Anticoagulants, in infective endocarditis,
neuropsychologic changes due to, 205- 433-434
218 Antiepileptic drug(s) (AEDs), in the
affect and cognitive factors, 210-211 elderly, 793-798
alcoholic history in, 211 interactions among, 905-922
childhood behavioral problems, 211- pharmacodynamic, 907-908
212 pharmacokinetic, 908-909
family history, 212 metabolism of, in pregnancy, 778
models, 207 new, 923-949
nature and severity of impairment, in pregnancy, 777-786
206-207 for seizures, 767-770
premature aging, 211 adverse effects, 770-771
prevalence, 205 Antioxidant(s), in epilepsy prevention,
Algorithm, point D2, ventricular fibrillation 829-830
and, 340-345 Antiperoxidant(s), in epilepsy prevention,
Alzheimer’s disease, depression in, 91 829
Amitryptiline, myasthenic effects Anxiety disorders, epilepsy and, 137-138
exacerbated by, 700 Aorta, coarctation of, neurologic
Amnesia, transient global, seizures and, complications, 446
744-745 Aortic stenosis, balloon valvuloplasty for,
394-395
Amnestic syndrome, and alcoholic
Aortic valve disease, stroke and, 392
dementia, 205-208
Aphasia Research Center at the Boston
Amphetamine(s), 670-675
Veterans Administration Hospital, 5
abuse of, clinical effects, acute, 541-542
Aprosodias, 13-16
cognitive effects, 688
defined, 13
movement disorders due to, 633
in tone languages, 16
muscular effects, 702
Aprosody, defined, 11
nerve root effects, 699
Arotic arch chemoreceptors, in neural
perceptual and psychomotor effects,
cardiovascular control, 258
672-675
Arrhythmia, 375-390. See also specific
peripheral nerve effects, 699 types, e.g., Bradyarrhythmia.
plexus effects, 699 brain regulation of, 329-330
seizures due to, 571-572 in CNS disease, 245-246, 248-250
stroke related to, 582-583 epilepsy and, 298-299
chemistry of, 671-672 fatal, brain mechanisms underlying, 325-
compulsive use of, 542 351. See also Neurocardiology.
dependence upon, 542 neural control of heart and, 248-250
described, 536-537 neurologic complications, 449-450
epidemiology, 670 stress-induced, 246, 302-304
hallucinogenic, 540-541 stroke and, 297-298, 387-388
history, 670-671 sudden death due to, 304, 326
pharmacology of, 539-540, 671-672 syncope and, 375-387
routes and patterns of administration, ventricular, pathogenesis, nervous sys-
537-538 tem in, experimental studies, 294—
tolerance to, 542 299
Analgesia, opioids and, 510 human studies, 299-301
Aneurysm, atrial septic, echocardiography Arrhythmogenesis, cerebrovascular disease
in, 359 and, 300-301
CUMULATIVE INDEX 1993 975
CNS in, 297-299, 300-301 history, 1-8
in normal hearts, brain regulation of, issue on, 1-231
330-338 neuropsychologic testing in, 219-231. See
parasympathetic nervous system in, 294— also Neuropsychologic testing, in be-
297, 299-300 havioral neurology.
stress and, 302-304 Benign paroxysmal vertigo of childhood,
Artificial heart, total, cerebrovascular seizures and, 743
complications, 465-466 Benzodiazepine(s), abuse of, 529-530
Asymmetry, brain, in developmental acute effects, 529-530
dyslexia, 162-165 overdose of, 529-530
Atherosclerosis, aortic, echocardiography withdrawal from, 530
in, 360-361 for status epilepticus, 845-851
Atrial fibrillation, echocardiography in, 358 Bilateral synchrony, secondary, 874
Atrial pressure/ volume receptors, in Bipolar affective disorder, in multiple
neural cardiovascular control, 258 sclerosis, 199
Atrial septal defect, silent, neurologic Blood viscosity, abnormalities in, total
complications, 444-446 artificial hearts and, 470-471
Atrioventricular conduction disturbances, Botulism, drug-related, 596
377-379 Bradyarrhythmia, syncope due to, 375-379
Attention, multiple sclerosis effects on, Brain, abscess of, drug-related, 596
192-193 asymmetry of, in developmental dys-
Attention deficit hyperactivity disorder, in lexia, 162-165
adults, 113-117 biopsy of, in HIV infection, 617-618
causes, 69 dysfunction of, in depression, 85-87
diagnostic criteria for, 61 imaging techniques of, 5
vigilance and, relationship between, 69 pathways to heart, 294
Attention deficit hyperactivity disorder in regulation of arrhythmias, 329-330
symptom complex, 69-71 in regulation of arrhythmogenesis in nor-
Auditory system, cocaine effects on, 718 mal hearts, 330-338
Aura(s), frontal lobe seizures and, 813 regulation of heart by, rationale, 327-329
temporal lobe seizures and, 806 regulation of heartbeat by, 329-330
Autism, clinical features, 176 tumors of, MRI detection of, 884-885
hypothesized abnormal circuit in, 183 Brain abscess, drug-related, 596
inferior olive and cerebellar nuclei in, infective endocarditis and, 425-426
180 neurologic complications, 447-448
limbic system involvement in, 176-177 Brain injury, seizures and, biochemical
neuropathologic studies of, 175-187 effects, 825
methods and materials, 175-181 mechanisms of, 824-825
responses to, alteration of, 829-830
Breath holding, 741-743
incidence, 741
Balloon valvuloplasty, for mitral stensosis pathophysiologic basis for, 742
and aortic stenosis, 394-395 reflex anoxic seizures and, 742-743
Barbiturate(s), absorption of, 914 types, 742
abuse of, 529-530 Broca, Paul, 3-4
acute effects, 529-530 Bromide, abuse of, 530-531
overdose of, 529-530 Buprenorphine, 507
withdrawal from, 530 for opioid addiction, 519
elimination of, 915 Buspirone, abuse of, 531
protein binding of, 915
Baroreceptors, in neural cardiovascular
control, 258
Behavior, changes in, epilepsy and, 127- Calciferol, in neurogenic heart disease,
149. See also Epilepsy, behavioral changes 285-286
associated with. Capillary permeability, altered, neurogenic
in childhood, and adult alcoholism, 211- pulmonary edema and, 313-314
212 Carbamazepine, absorption of, 911
neurology of, 1 drug interactions with, 912
Behavioral neurology, defined, 1 elimination of, 911-913
976 CUMULATIVE INDEX 1993
Carbamazepine (Continued) Cerebrocortical anomalies, in
for epilepsy in the elderly, 795-796 developmental dyslexia, 165-169
metabolism of, 911-913 Cerebrospinal fluid examination, in
protein binding of, 911 infective endocarditis, 429-430
Carbamazepine syndrome, 782 Cerebrovascular accidents, cocaine and,
Cardiac. See Heart. 546-547
Cardiac afferents, neuroanatomy, 240-241 Cerebrovascular disease, arrhythmogenesis
Cardiac catheterization, neurologic and, 300-301
complications, 450-451 drug-related, 578
Cardiac efferents, neuroanatomy, 241-242 seizures and, 745-746
Cardiac lesions, right-to-left shunt, in the elderly, 790-791
neurologic complications, 441-444 Children, seizures and epilepsy in, 755-775
Cardiac surgery, neurologic complications, Chorioretinitis, drug-related, 595
452-454 Cingulate gyrus, seizures in, 816
Cardiac valvular disease, echocardiography Circulatory support devices, artificial,
in, 361-362 blood-artificial surface interactions in,
Cardiovascular regulation, neuroanatomy, 471-472
240-242 centrifugal pumps, 464-465
Cardiovascular status, neural control of, cerebrovascular complications, 463-474
afferent limb, 258-259 disturbed blood flow patterns in, 470
efferent limb, 259-262 infection in, 471
Carotid sinus chemoreceptors, in neural rheologic factors in, 470-471
cardiovascular control, 258 total artificial heart, 465-466
Carotid sinus sensitivity, 739-740 types, 464-470
Cataplexy, 747-748 ventricular assist devices, 466-470
Catecholamines, in neurogenic heart Clobazam, described, 925
disease, 246-247, 284-285 Clonidine, for opioid addiction, 519
Catheterization, cardiac, neurologic CNS. See Central nervous system.
complications, 450-451 Cocaine, abuse of, cerebral vasculitis due
CBAG surgery. See Coronary artery bypass to, 547
graft (CABG) surgery. cerebrovascular accidents due to, 546-
Central nervous system (CNS), in 547
arrhythmogenesis, 297-299, 300-301 clinical effects, acute, 541-542
cardiac damage by, 273-292 CNS infection due to, 547-548
in CBAG surgery, 475-495. See also Coro- cognitive effects, 688
nary artery bypass graft (CABG) sur- fetal effects, 715-719
gery. auditory, 718
in fetal alcohol syndrome, 713-714 intrauterine growth, 716
neuroanatomy, 275-276 neurobehavioral, 717
Central nervous system (CNS) disease, neurodevelopmental, 718-719
arrhythmias in, 245-246, 248-250 seizures, 717-718
ECG changes in, 257-272 SIDS, 718
morphology, 262-266 stroke, 717
rhythm disturbances and, 267 movement disorders due to, 545, 631-
Central nervous system (CNS) infection, 633
cocaine and, 547-548 muscular effects, 701
Central pontine myelinolysis, ethanol and, myasthenic effects exacerbated by,
528 699-700
Centrifugal pumps, cerebrovascular neurologic complications, 543-549
complications, 464-465 long-term, 548-549
Cerebellar degeneration, alcoholic, 628 pregnancy effects, 545-546, 716
Cerebral dysfunction, in depression, 85-87 rhabdomyolysis due to, 548
Cerebral embolism, infective endocarditis seizures due to, 543-544, 569-571
and, 424-425 spinal cord diseases associated with,
Cerebral ischemia, echocardiography in, 694-695
357-363 stroke related to, 581-582
Cerebral microemboli, following CBAG sudden death syndrome due to, 544
surgery, 481-493 tic disorders due to, 545
Cerebral vasculitis, cocaine-associated, 547 withdrawal symptoms, 719
CUMULATIVE INDEX 1993 977
childhood exposure to, 719 primary, 646-655
compulsive use of, 542 clinical evidence of, 647-650
dependence upon, 542 CT in, 651-653
described, 536 MRI in, 651-652
dystonic reactions to, 545 neuropathologic evidence, 653-655
pharmacology of, 538-539 pneumoencephalography in, 651-
routes and patterns of administration, 653
537-538 psychologic evidence of, 650-651
tolerance to, 542 radiologic evidence of, 651-653
uses, 536 subcortical, multiple sclerosis as, 200-201
Cognitive impairment, in alcoholism, 212- Dependence, psychological, described, 509
213 Depression, 79-104
in multiple sclerosis, 189-197. See also Alzheimer’s disease and, 91
Multiple sclerosis, cognitive impairment cerebral dysfunction in, 85-87
in. conditions complicated by, 82
Cognitive/motor complex, HIV-1-- dementia and, 90-91
associated, 612 epilepsy and, 90, 135
Computed tomography (CT), in alcohol- multiple sclerosis and, 90, 198-199
related seizures, 568-569 myotonic dystrophy and, 90
in alcoholic dementia, 651-653 neurobiologic correlates of, 80-92
in cardiac lesions, 442-444 neurochemical basis of, 91-92
in infective endocarditis, 427-429 neuroendocrine dysfunction in, 83-84
in multiple sclerosis, 196-197 neurologic diseases associated with, 87-
single-photon emission, in epilepsy, 894- 91
897 neurology of, implications for, 92-93
Confusion, cognitive rehabilitation in, 46- neurophysiologic changes in, 80-83
47 Parkinson’s disease and, 89-90
Congenital heart disease. See Heart disease, poststroke, 19
congenital. stroke and, 87-89
Constipation, opioids and, 510-511 symptoms, 81
Coronary artery bypass graft (CABG) symptoms complex of, 80
surgery, cerebral microemboli “Designer drugs,” 507-509, 683-684
following, 481-493 abuse of, cognitive effects, 688
CNS complications, 475-495 opioid, 507-509
prevalence, 475-477 Development, epilepsy during pregnancy
hypotension following, 479-481 effects on, 779-782
nonpulsatile cerebral perfusion in, 490 Diazepam, for status epilepticus, 845-851
stroke following, 478-479 Dissociative disorders, psychiatric, epilepsy
transcranial Doppler analysis during, and, 138-139
487-488 Drug(s). See also specific types and drug
Coronary artery disease, 399-417 ames.
echocardiography in, 3 abuse of. See Drug abuse.
in neurovascular disease, 363 antiepileptic. See Antiepileptic drug(s).
prevalence, 363 “designer,” 683-684
screening for, 363-366 abuse of, cognitive effects, 688
testing for, 366-367 overdose of, seizures and, 746-747
Corpus callosotomy, in epilepsy, 966 Drug abuse. See also Substance abuse.
Cough suppression, opioids and, 511 amphetamines, 670-675
“Crack”, described, 536 anticholinergics, 559
muscular effects, 701 barbiturates, 529-530
CT. See Computed tomography. benzodiazepines, 529-530
cerebrovascular disease due to, 578
“designer drugs,” 683-684
ethanol, 523-529
Death, sudden. See Sudden death. fetal effects, 707-728
Deja vu, temporal lobe seizures and, 807- hallucinogens, 557-558, 681-683
hypnotics, 675-677
Delirium tremens, ethanol and, 526 infections due to, 591-603
Dementia, alcoholic, 205-208 botulism, 596
978 CUMULATIVE INDEX 1993
Drug abuse (Continued) Echocardiography, in cardiac surgery, 368-
brain abscess, 596 369
chorioretinitis, 595 in cerebral ischemia, 357-363
endophthalmitis, 595 in coronary artery disease, 363-367
fasciitis, 593-594 in infective endocarditis, 430-431
frontal osteomyelitis, 596 intraoperative, 367-369
hepatitis, 598-599 in neurologic disorders, 353-374
infective endocarditis, 591-592 in noncardiac surgery, 367-368
malaria, 598 in syncope, 369
meningitis, 596 techniques, 354-357
optic neuropathy, 596 “Ecstasy,” 540-541, 683-684
pyomyositis, 593-594 ECT. See Electroconvulsive therapy.
sinusitis, 596 Edema, pulmonary. See Pulmonary edema.
social implications, 600 opioids and, 513
syphilis, 598 EEG. See Electroencephalography.
tetanus, 594-595 Efferent nerve fibers, cardiac, 241-242
tuberculosis, 599-600 Efferent receptors, in neural cardiovascular
vertebral and epidural spinal, 596-598 control, 259-262
inhalants, 558-559, 677-681 Elderly, seizures and epilepsy in, 787-804.
intravenous, infective endocarditis and, See also Seizure(s), in the elderly.
422 Electrocardiography (ECG), in CNS
disease, 257-272
long-term, cognitive effects, 688
morphology, 262-266
marijuana, 556-557, 664-670
in heart function, 244-245, 246-248
MDMA, 683-684
neurogenic changes in, 262-268
muscle disorders due to, 700-702
defined, 281
neurologic complications, issue on, 503-
Electroconvulsive therapy (ECT), in grand
mal seizures, 152-153
neuromuscular junction effects, 700
Electroencephalography (EEG), in alcohol-
opiates, 685-687
related seizures, 568
opioids, 503-521
in epilepsy, 857-881. See also Epilepsy,
phencyclidine, 555-556
EEG interpretation in.
psychostimulants, 535-553
intracranial, in epilepsy, 960-964
sedatives, 675-677
in Parkinson’s disease, 862
seizures related to, 563-575. See also Sei-
for seizures in the elderly, 791-792
zure(s), drug-related.
in temporal and frontal lobe epilepsies,
stroke related to, 577-590. See also
817
Stroke, drug-related.
Embolism, cerebral, infective endocarditis
Dyskinesia(s), alcohol-related, 627-628 and, 424—426
Dyslexia, in adults, 107-112 paradoxic, echocardiography in, 359
imaging techniques in, 108-110 Embolus(i), foreign body, stroke and, 579
developmental, anatomic and pathologic Emotion(s), ictal, temporal lobe seizures
changes in, causes, 169-170 and, 808
brain asymmetry in, 162-165 lateralization of, 19-20
cerebrocortical anomalies in, 165-169 neurology of, 17-20
hallmark of, 161 Emotional disturbances, in multiple
microdysgenesis in, 166-168 sclerosis, 197-201
microgyria in, 166-168 Encephalopathy, hepatic, ethanol and, 528
neuroanatomic basis of, 161-173 HIV infection and, 614-616
visual pathway changes in, 169 Wernicke, defined, 639
genetics of, 110-112 ethanol and, 526
Dysmorphism, facial, 782 Endocarditis, infective, antibiotics in, 431-
Dysplasia, MRI detection of, 885-886 432
Dysprosody, defined, 11 anticoagulants in, 433-434
Dystonia, cocaine and, 545 brain abscess in, 425-426
cardiac surgery in, 434-435
cerebral embolism in, 424-425
clinical presentation, 424-427
EGG. See Electrocardiography. diagnosis, 427-431
CUMULATIVE INDEX 1993 979
drug-related, 591-592 identification of normal transients,
encephalopathy in, 426 864-867
epidemiology, 419-422 pitfalls of, 877-879
headache in, 426 quantitative recordings, pitfalls of,
incidence, 419-420 878-879
intracranial mycotic aneurysm in, 425 significant epileptiform activity, analy-
in intravenous drug users, 422 sis of, 873-877
location in, 420-421 EEG monitoring in, intracranial, 960-964
management, 431-435 in the elderly, 787-804. See also Sei-
meningitis in, 425-426 zure(s), in the elderly.
microbiology of, 422-423 causes, 788, 789
neurologic complications, 419-440, 447 incidence, 787-788
neurosurgery in, 432 prevalence, 787-788
pathogenesis, 423-424 genius and, 133
prognosis, 435 incidence, 777, 787-788
prosthetic valve, 421-422 in infants and children, 755-775
seizures in, 426 MRI in, 884-889
stroke and, 577-578 neurogenic pulmonary edema and, 312-
visual disturbances in, 427 313
Endophthalmitis, drug-related, 595 neuroimaging in, 883-903
personality changes due to, 127
Ephedrine, abuse of, stroke related to, 583
PET in, 889-893
pharmacology of, 540
positive traits in, 133
Epilepsia partialis continua, 838
pregnancy and, 777-786. See also Preg-
Epilepsy. See also Seizure(s).
nancy, epilepsy in.
alcoholism and, 568
prevalence, 737
arrhythmias and, 298-299
psychopathology in, 133-135
behavioral changes associated with, 127-
factors contributing to, 134
149
psychosocial stigma associated with, 738
aggression, 139-140
SPECT in, 894-897
altered sexuality, 131
sudden death and, 301
anxiety disorders, 137-138
surgery for, 951-971
depression, 135
contraindications, 954-955
dissociative disorders, 138-139
corpus callosotomy, 966
fear, 138
focal resective, 964-966
historical perspective, 128-129
for infantile spasms, 967
hypergraphia, 133
frontal lobectomy, 965-966
methodologic issues in, 129-130 frontiers of, 967
pathogenesis, 141-142 hemispherectomy, 967
personality changes due to, 130-133 invasive evaluation, 959-960
psychosis, 135-137 multiple subpial transections, 968
religiosity, 131-132 occipital lobectomy, 966
viscosity, 132-133 parietal lobectomy, 966
cocaine-related seizures and, 570-571 patient selection for, 952-955
cryptogenic, 756 presurgical evaluation, 955-959
depression in, 90 temporal lobectomy, 966-967
described, 737 temporal lobe, interictal hyposexuality
diagnosis and treatment, issue on, 737— in, 131
971 types, 755-756
drugs for, interactions among, 905-922 Epilepsy syndrome, defined, 755
EEG interpretation in, 857-881 Epileptogenesis, cellular mechanisms of,
assessment of transient or intermittent 826
activities, 859-860 Episodic dyscontrol, seizures and, 748-749
background activities, 857-859 Essential myoclonus, alcohol-related, 626
benign epileptiform variants, 868-873 Essential tremor (ET), alcohol-related, 625-
identification of activity as cerebral in 626
origin, 860-864 Ethanol. See also Alcohol.
identification of nonspecifically abnor- abuse of, acute effects, 524-526
mal activities, 867-868 altered mentation due to, 639-661
980 CUMULATIVE INDEX 1993
Ethanol (Continued) efficacy of, 942
central pontine myelinolysis due to, mechanisms of action of, 942
528 pharmacokinetics of, 942-943
cerebellar degeneration due to, 527 Fluorocortisol, in neurogenic heart disease,
chronic effects, 526-529 285-286
hypoglycemia due to, 529 18-F-Fluorodeoxyglucose (FDG), in
intoxication due to, 524 epilepsy, 889-892
Korsakoff amnestic syndrome due to, Foreign body emboli, stroke and, 579
527
Marchiafava-Bignami disease due to,
528
neurologic complications, 523-529 Gabapentin, absorption of, 917
overdose due to, 524 adverse effects, 931-932
pellagra due to, 527 chemical structure of, 906
Wernicke encephalopathy due to, 526 clinical use, 932
withdrawal from, delirium tremens described, 925
due to, 526 drug interactions with, 932
withdrawal from, 525-526 efficacy of, 930-931
seizures due to, 525-526 elimination of, 917-918
Ethchlorvynol, abuse of, 531 mechanisms of action of, 930
Euphoria, in multiple sclerosis, 198 metabolism of, 917-918
Executive dysfunction, 115-117 pharmacokinetics of, 931
protein binding of, 917
Gall, Franz Joseph, 2, 3
Gene(s), as factor in post-traumatic
Facial dysmorphism, 782 seizures, 826-827
Fasciitis, drug-related, 593-594 Geschwind, Norman, 3, 4-5
Fear, ictal, epilepsy and, 138 Gestures, comprehension of, 15-16
Felbamate, absorption of, 916 defined, 11-12
adverse effects, 928 Gesturing, spontaneous affective prosody
chemical structure of, 906 and, 13
clinical use, 929-930 Glutathione, in epilepsy prevention, 829
described, 925 Glutethimide, abuse of, 531
drug interactions with, 928-929
efficacy of, 927
elimination of, 916-917
mechanisms of action of, 926 Hallucination(s), temporal lobe seizures
metabolism of, 916-917 and, 809-810
pharmacokinetics of, 927 Hallucinogen(s), 681-683
Fentanyl, 507 abuse of, cognitive effects, 688
Fetal alcohol syndrome (FAS), 712-715 perceptual and psychomotor effects,
CNS involvement in, 713-714 682-683
growth-related effects, 713 side effects, 557-558
incidence, 712 chemistry of, 681-682
malformations due to, 712-713 described, 557
Fetal hydantoin syndrome (FHS), 781 epidemiology, 681
Fetal trimethadione syndrome, 781 history, 681
Fetus, alcohol abuse effects on, 711-715 pharmacology of, 681-682
cocaine effects on, 715-719 Hashish, high school students’ use of, 664
drug effects on, 707-728 Headache, infective endocarditis and, 426
marijuana, 710-711 Heart, artificial, cerebrovascular
opiate effects on, 719-722 complications, 465-466
smoking effects on, 708-710 disturbed blood flow patterns in, 470
Flourens, 2 brain regulation of, rationale, 327-329
Flunarizine, adverse effects, 943 damage to, neurally induced, 273-292
chemical structure of, 906 function of, autonomic influences on,
clinical use, 944 242-243
described, 925 catecholamines and, 246-247
drug interactions with, 943-944 clinical observations, 243-246
CUMULATIVE INDEX 1993 981
ECG changes in, 244-245, 246-248 Hexamethylpropyleneamineoxime
experimental studies, 246-250 (HMPAO), in epilepsy, 894-896
parasympathetic control of, 261-262 Himmelsbach system for withdrawal
pathophysiology, 246-250 behavior, 508
sympathetic control of, 259-261 HIV infection. See Human immunodeficiency
neural control of, 239-256, 257 virus (HIV) infection.
neuroanatomy, 274-278 Horner’s syndrome, surgery and, 454
pathways to brain, 294 Human immunodeficiency virus (HIV)
surgery of, in infective endocarditis, 434— infection, 605-624
435 brain biopsy in, 617-618
Heart disease, congenital, neurologic classification, 607-609
complications, 441-462 clinical syndromes of, 609
arrhythmias, 449-450 cognitive /m otor complex related to, 612
brain abscess, 447-448 epidemiology, 605-607
coarctation of the aorta, 446 etiopathogenesis, 607-609
congenital, 448-449 neoplasms and, 613-617
infective endocarditis, 447 neurologic syndromes of, 610-613
postsurgical, 454 opportunistic infections and, 613-617
preexisting, 448-449 '3]-Hydroxyiodo-propyldianine (HIPDM),
in epilepsy, 894-896
procedure-related, 450-458
right-to-left shunt lesions, 441-444 Hypergraphia, epilepsy and, 133
Hyperprosody, defined, 11
silent atrial septal defect, 444-446
Hypersynchrony, hypnogogic, 865
spontaneous, 441-450
Hypertension, acute, stroke and, 579
ventricular septal defect, 446
Hyperventilation, seizures and, 743
neurogenic, 281-290
Hypnotic(s), 675-677
catecholamine infusion in, 284-285
abuse of, cognitive effects, 688
history of, 281-284
perceptual and psychomotor effects,
nervous system stimulation in, 286-
676-677
287
epidemiology, 675
pathogenesis, 289
history, 675-676
production of, 284-290
Hypoglycemia, ethanol and, 529
reperfusion in, 288-290
Hypotension, following CBAG surgery,
steroids in, 285-286
479-481
stress in, 285-286
Hypothalamic lesions, pulmonary edema
Heart transplantation, cerebrovascular
in, 311-312
complications, 463-474
Hypovigilance, 69-71
Heartbeat, low-dimensional chaos in, and
ventricular fibrillation, 340-345
patterns of, ventricular fibrillation due
to, 345-348 Illusion(s), temporal lobe seizures and,
prediction of, 338-339 809-810
variability of, brain regulation of, 329- Imaging techniques, for brain, 5
330 Infant(s), seizures and epilepsy in, 755-775
Hemispherectomy, in epilepsy, 967 Infantile spasm(s), 759-760
Hemorrhage, intracranial, risk of, in focal resective surgery for, 967
myocardial infarction, 412-413 Infection, artificial hearts and, 471
Hepatic encephalopathy, ethanol and, 528 drug-related, 591-603
Hepatitis, drug-related, 598-599 spinal, epidural, drug-related, 596-598
Hepatocerebral degeneration, acquired, vertebral, drug-related, 596-598
645-646 Infective endocarditis. See Endocarditis,
Heroin, abuse of, fetal effects, 719-722 infective.
seizures due to, 572 Information processing, multiple sclerosis
spinal cord diseases associated with, effects on, 192-193
695-696 Inhalant(s), 677-681
stroke related to, 582 abuse of, cognitive effects, 688
cost of, 504 nerve root effects, 699
street use of, 503-504 peripheral nerve effects, 699
Heterotopia(s), MRI detection of, 885-886 plexus effects, 699
982 CUMULATIVE INDEX 1993
Inhalant(s) (Continued) Left ventricular aneurysm, posinfarction,
side effects, 558-559 405-406
chemistry of, 678 Lennox-Gastaut syndrome, 760-761
described, 558 Limbic system, in autism, 176-177
epidemiology, 677 Liver disease, alcoholic, movement
history, 678 disorders associated with, 628-629
perceptual and psychomotor effects, 678- Lobectomy, frontal, in epilepsy, 965-966
680 occipital, in epilepsy, 966
pharmacology of, 678 parietal, in epilepsy, 966
Intelligence, multiple sclerosis effects on, temporal, in epilepsy, 966-967
191-192 Lorazepam, for status epilepticus, 845-851
Intracranial pressure, neurogenic LSD (lysergic acid diethylamide), 681-683
pulmonary edema and, 312 abuse of, stroke related to, 584
Intrauterine growth, cocaine effects on, 716 Lung(s), neuroanatomy, 274-278
'3]-N-Isopropyl-iodoamphetamine (IMP), Lung disease, neurogenic, 278-281
in epilepsy, 894-896 Lung fluid flux, physiology of, 309-311
Lymphoma, HIV infection and, 616
Lysergic acid diethylamide (LSD), 681-683
abuse of, stroke related to, 584
Jactatio capitis, 747
Jamais vu, temporal lobe seizures and,
807-808
Magnetic resonance imaging (MRI), in
alcoholic dementia, 651-652
in cardiac lesions, 442-444
in dyslexia, 108-109
Khat shrub, 540
in epilepsy, 884-889
Kinesics, 11-12
abnormalities found, 884-887
affective, in right hemisphere, organiza-
in clinical management, 887-889
tion of, 12-17
future directions, 889
defined, 11
in infective endocarditis, 428-429
gestural, 11-12
in multiple sclerosis, 196-197
Korsakoff’s syndrome, 205-218, 640
Malaria, drug-related, 598
determinants of, 208
Mania, following stroke, 88-89
ethanol and, 527
Marchiafava-Bignami disease, 644-645
recovery from, 208
ethanol and, 528
Marijuana, 664-670
abuse of, cognitive effects, 688
fetal effects, 710-711
Lamotrigine, absorption of, 918
muscular effects, 702
adverse effects, 934
perceptual and psychomotor effects,
chemical structure of, 906 665-667
clinical use, 935-936 prenatal effects, 667
described, 925 side effects, 556
drug interactions with, 935 stroke related to, 585
efficacy of, 933-934 studies of, 668-669
elimination of, 918 adolescent user effects, 667-668
mechanisms of action of, 932-933 chemistry of, 665
metabolism of, 918 described, 556
pharmacokinetics of, 934 epidemiology, 664
protein binding of, 918 high school students’ use of, 664
Language, multiple sclerosis effects on, 192 history, 664-665
nonverbal aspects of, 9-23 pharmacology of, 665
tone, aprosodias in, 16 Melancholia, 79-104. See also Depression.
Laughing, pathologic, in multiple sclerosis, Memory, multiple sclerosis effects on, 193-
198 195
Learning disabilities, in adults, 105-125 Meningitis, drug-related, 596
nonverbal, in adults, 118-121 HIV infection and, 614
Learning disabled, defined, 105 infective endocarditis and, 425-426